Search
lucinactant (Surfaxin)
Indications:
- prevention of respiratory distress syndrome in premature infants
Dosage:
- administered by endotracheal tube
Adverse effects:
- most common adverse effects related to use of endotracheal tube
Mechanism of action:
- pulmonary surfactant
Related
beractant (Survanta)
calfactant (Intrasurf)
General
pulmonary agent
References
- FDA News Release March 6, 2012
FDA approves Surfaxin to prevent breathing disorder in premature infants
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294984.htm